Do Not Treat Morganella morganii in Urine if the Patient is Asymptomatic
The decision to treat Morganella morganii isolated from urine depends entirely on whether the patient has urinary tract symptoms—asymptomatic bacteriuria should NOT be treated in most populations, while symptomatic UTI requires antimicrobial therapy.
Clinical Decision Algorithm
Step 1: Assess for Urinary Tract Symptoms
Symptomatic UTI (requires treatment):
- Lower tract: dysuria, frequency, urgency, suprapubic pain
- Upper tract: fever, flank pain, costovertebral angle tenderness
- Systemic signs: elevated inflammatory markers (CRP, PCT), leukocytosis
Asymptomatic bacteriuria (generally do NOT treat):
- Positive urine culture with ≥10⁵ CFU/mL
- No urinary symptoms
- No systemic signs of infection
Step 2: Apply Evidence-Based Treatment Guidelines
DO NOT TREAT Asymptomatic Bacteriuria in:
The 2024 EAU guidelines provide a strong recommendation against screening or treating asymptomatic bacteriuria in 1:
- Women without risk factors
- Patients with well-regulated diabetes mellitus
- Postmenopausal women
- Elderly institutionalized patients
- Patients with dysfunctional/reconstructed lower urinary tract
- Renal transplant recipients
- Patients before arthroplasty surgery
- Patients with recurrent UTIs
The 2019 IDSA guidelines emphasize that treating asymptomatic bacteriuria drives antimicrobial resistance without patient benefit, and that bacteriuria may actually protect against symptomatic UTI 2.
DO TREAT Asymptomatic Bacteriuria ONLY in:
- Pregnant women (weak recommendation) 1
- Before urological procedures breaching the mucosa (strong recommendation) 1
Step 3: If Treatment is Indicated, Consider M. morganii Resistance Patterns
M. morganii has intrinsic resistance to certain antibiotics commonly used for UTIs:
Uniformly resistant to:
Typically susceptible to:
- Carbapenems (imipenem, meropenem, ertapenem) - 100% susceptibility 4, 5, 6
- Piperacillin-tazobactam - 100% susceptibility 4, 6
- Cefepime (4th generation cephalosporin) - 100% susceptibility 3, 4
- Ceftazidime (3rd generation) 4
- Amikacin 3, 5
- Fluoroquinolones (variable resistance, check local susceptibilities) 6
Important Clinical Caveats
Risk factors for M. morganii UTI:
- Urological abnormalities (neurogenic bladder, myelomeningocele) 3
- Immunosuppression (chemotherapy, immunosuppressant therapy) 4
- Catheter use 3
- Underlying nephrotic syndrome 4
Common pitfall: Treating positive urine cultures reflexively without assessing symptoms. The 2019 IDSA guidelines specifically identify this as a major driver of inappropriate antimicrobial use and resistance 2. A positive culture alone does NOT equal infection requiring treatment.
Pediatric considerations: M. morganii UTIs in children are often associated with underlying urological abnormalities (44% with neurogenic bladder) 3. Most pediatric cases present as lower UTIs with mild symptoms and respond well to third-generation cephalosporins 4.
Avoid empiric therapy with: Nitrofurantoin and amoxicillin-clavulanate are ineffective against M. morganii due to intrinsic resistance mechanisms 3, 4. If M. morganii is suspected or confirmed, switch to appropriate agents based on susceptibility testing.
Multidrug resistance: Hospital-acquired M. morganii strains show higher rates of ESBL production (10%) and multidrug resistance compared to community strains 7, 5. Always obtain antimicrobial susceptibility testing for symptomatic infections to guide definitive therapy.